drugset
drugset / Trial / NCT05330858

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858 ↗

Phase 1 Completed 14 enrolled Alumis Inc
RandomizedCrossoverOpen-labelBasic science

Summary

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Timeline

Start
2022-03-17
Primary completion
2022-06-30
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ENVUCITINIB Small molecule — Oral
Subject Rabeprazole Small molecule — Oral

Indications

No indication recorded.